You are here

Shire

Does a $50B-plus Shire buyout even make sense for Takeda? Maybe not

Endpoints

Wed, 03/28/18 - 07:16 pm

Drugmaker Shire soars as Japan's Takeda considers bid

CNBC

Wed, 03/28/18 - 10:13 am

Court Dismisses FTC’s Citizen Petition Complaint Against Shire

RAPS.org

Tue, 03/27/18 - 10:50 am

citizen petitions

Shire CEO sees Microsoft tie-up building momentum for faster rare disease diagnosis

Fierce Pharma

Wed, 03/21/18 - 11:28 pm

Flemming Ornskov

Ocugen’s Dry Eye Disease Therapy Could Compete with Allergan and Shire

Xtalks

Wed, 03/21/18 - 10:55 am

dry eye disease

Top 5 boards for week ending March 10, 2018

CP Wire

Sun, 03/11/18 - 03:05 pm

Shire's HAE candidate boosted by new Phase 3 data

Biopharma Dive

Tue, 03/6/18 - 09:31 am

clinical trials

Top 5 viewed boards for week ending March 3, 2018

CP Wire

Sun, 03/4/18 - 01:50 pm

Analyzing the orphan drugs market ($127bn)

GoinPharma

Fri, 03/2/18 - 09:48 am

Why big pharma companies always create new spinoffs

GoinPharma

Sun, 01/28/18 - 10:06 am

Shire set for in-house production of rare disease drug Cinryze after shortage issues

Fierce Pharma

Thu, 01/25/18 - 12:00 am

drug manufacturing

Shire's latest approval won't save it from Hemlibra

Biopharma Dive

Wed, 01/17/18 - 09:58 pm

Shire CEO Flemming Ornskov is hatching a few new stretch goals for R&D in 2018 — and beyond

Endpoints

Fri, 01/12/18 - 10:36 am

Flemming Ornskov

JPM18: Shire holds onto neuroscience unit, for now

Biopharma Dive

Mon, 01/8/18 - 10:04 pm

Shire creates separate neurosciences division for future investments; Agenus gains $28M in royalty deal

Endpoints

Mon, 01/8/18 - 11:26 am

Shire seeks FDA sign-off on plasma manufacturing facility

Biopharma Dive

Sat, 01/6/18 - 12:28 pm

drug manufacturing

Shire hit by a setback as Hunter syndrome drug fails late-stage study

Endpoints

Tue, 12/19/17 - 12:04 pm

Hunter Syndrome

clinical trials

Shire looks to stall Hemlibra impact with court injunction

BioPharma Dive

Tue, 12/19/17 - 12:03 pm

Pages